Alphamab prices HK IPO, eyeing over USD 200m



Suzhou-based biotech Alphamab Oncology announced pricing for an initial public offering (IPO) to the Hong Kong Stock Exchange (HKEX). The firm plans to issue 179.4 million shares priced at HKD 9.1 to HKD 10.2 per share, with the listing to take place on December 12. Top pricing would give a maximum take-home of HKD 1.83 billion (USD 233 million).

Alphamab has developed several proprietary technology platforms for bispecific and mixed antibodies, and currently has eight oncology drug candidates in the pipeline, including four in clinical development. Core product KNO46 is a potential first-in-class bispecific antibody against both cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death-1 (PD-1), currently at the Phase Ib/II trial stage and set to be fast-tracked by Alphamab towards a first Biologics License Application (BLA) in nasopharyngeal carcinoma in 2022. Other candidates include anti-HER2 bispecific antibody KNO26, and programmed death ligand-1 (PD-L1) inhibitor KNO35, described as potentially the world’s first PD-L1 subcutaneous injection. KNO35 was licensed to compatriot firm Ascletis Pharma Inc., (HK.1672) for co-development of the drug as a therapy against the hepatitis B virus.

Alphamab has yet to enter the commercial stage; revenue streams include bank interests and government subsidies. The company posted RMB 203 million in net losses in 2018. Proceeds of the IPO will go towards clinical development, establishing facilities for manufacturing and research and development, and operating capital.

Reference:

Related news
Harbour Bio’s next-gen CTLA-4 antibody enters trials in Australia Harbour BioMed, which operates out of sites in China, the US, and The Netherlands, announced the start of clinical development for HBM4003, a next-generation checkpoint inhibitor against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
Beijing-based 3D Medicines Corporation published the results of a Phase I clinical study for anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb) envafolimab (KN035) carried out in Japan, at this year's Chinese Society of Clinical Oncology (CSCO) meeting.
Hangzhou-based biotech Ascletis Pharma Inc., (HK.1672) released financial results for H1’19, when product sales revenues related to hepatitis C virus (HCV) therapy Ganovo (danoprevir) more than doubled to RMB 55.35 million (USD 7.79 million), up 109.9%.
China-based biotech Ascletis Pharma Inc., (HK.1672) announced the opening of a clinical development center in Shanghai.
The Suzhou-based biotech Alphamab Oncology issued a prospectus in support of an initial public offering (IPO) to the Stock Exchange of Hong Kong (HKEX), published to the HKEX website on July 15, 2019.
Recent news
Chile’s Ministry of Health (MINSAL) this week announced measures against gender and age inequalities regarding Welfare Health Institutions (ISAPREs) fees.
Brazil-based Biolab, the leading seller of cardiology medicines in the Brazilian market, has signed an agreement with France-based Quantum Genomics to partner on the development, production, and commercialization in Latin America of a novel treatment for hypertension.
According to preliminary data from Mexico’s 2018 National Health and Nutrition Survey (ENSANUT), chronic diseases have continued to increase in the country since the previous survey in 2012.
Shandong province is set to scrap mark-ups on medical consumables at public medical institutions, according to a document released by the province.
US-based AbbVie’s Bruton’s tyrosine kinase (BTK) inhibitor ABBV-105 and Janus kinase 1 (JAK1) inhibitor upadacitinib (trade name: Rinvoq) have both won clinical trial approvals from the Center for Drug Evaluation (CDE).
China’s national drug use monitoring platform, online since November 25, now covers a network of 8,840 medical institutions and is handling an average 600,000 person visits daily, according to the National Healthcare Commission (NHC).
US-based biotech Amgen (Nasdaq.AMGN) trumpeted a new indication approval for its PCSK9 inhibitor Repatha (evolocumab) in China.
Analytics Snapshot